Peer Exchange

Shreyaskumar R. Patel, MD; Priscilla Merriam, MD; Richard F. Riedel, MD; and Gina Z. D'Amato, MD, discuss how gastrointestinal stromal tumors require comprehensive mutational analysis to guide targeted kinase inhibitor therapy, emphasizing the importance of patient adherence, proactive adverse effect management, and maintaining some form of kinase inhibition even after progression to maximize disease control and quality of life.

Panelists discuss the latest data on first-line treatment options for EGFR-mutated NSCLC, including CNS efficacy, and explore strategies for managing adverse events and sequencing therapies to optimize long-term outcomes.

Heather McArthur, MD; Laura Huppert, MD; Ruta Rao, MD; William J. Gradishar, MD, FACP; and VK Gadi, MD, PhD, discuss how recent ASCO 2025 data from DESTINY-Breast09 and other studies are reshaping first-line treatment decisions for HER2-positive metastatic breast cancer, with experts debating optimal sequencing strategies between trastuzumab deruxtecan (T-DXd), the CLEOPATRA regimen, and CDK4/6 inhibitor combinations while considering patient-specific factors like central nervous system metastases, hormone receptor status, and quality of life preferences.

Leslie M. Randall, MD; Thomas C. Krivak, MD; Rebecca C. Arend, MD, MPH; Tara Berman, MD, MS, Gottfried E. Konecny, MD discusses how molecular testing and biomarker-driven treatment strategies are revolutionizing gynecologic oncology across ovarian, cervical, and endometrial cancers.

Rebecca Shatsky, MD; Rita Nanda, MD; Kelly McCann, MD, PhD; Nusayba Bagegni, MD; and Alexis LeVee, MD,discuss how recent advances in hormone receptor–positive breast cancer treatment, including oral SERDs such as elacestrant, PI3K pathway inhibitors, and antibody-drug conjugates such as T-DXd, are being integrated into clinical practice based on biomarkers such as ESR1 mutations and HER2-low expression while addressing key sequencing decisions and resistance mechanisms in the evolving therapeutic landscape.

John L. Marshall, MD; Marwan G. Fakih, MD; Arvind N. Dasari, MD, MS, MD, and Katrina S. Pedersen, MD discuss how precision medicine has transformed metastatic colorectal cancer treatment through comprehensive molecular testing, targeted therapies like BRAF/EGFR inhibition and immunotherapy combinations for MSI-high tumors, and personalized approaches to treatment sequencing and dosing modifications that balance efficacy with quality of life considerations.

Luciano Costa, MD, PhD; Jing Christine Ye, MD, MSc; Samer Al Hadidi, MD, MS; and Binod Dhakal, MD, discuss how the multiple myeloma treatment landscape has evolved with quadruplet therapies becoming standard for newly diagnosed patients regardless of transplant eligibility, CAR T and bispecific antibodies showing promise for earlier use in relapsed/refractory disease, and emerging dual-targeting therapies potentially offering cure for some patients rather than just prolonged treatment.

Daneng Li, MD; Lowell B. Anthony, MD, FACP; Christopher Lieu, MD; and Chandrikha Chandrasekharan, MBBS, discuss how the treatment landscape for neuroendocrine tumors has evolved significantly over the past few decades with the introduction of multiple therapeutic options including somatostatin analogs, targeted therapies like everolimus and sunitinib, peptide receptor radionuclide therapy (PRRT), and the recent approval of cabozantinib, which provides new sequencing opportunities and fills treatment gaps for heavily pretreated patients while emphasizing the importance of individualized patient care and shared decision-making in this complex disease.

David C. Fisher, MD; Lauren C. Pinter-Brown, MD; Barbara Pro, MD, and Sima Rozati, MD, PhD discuss how to optimize cutaneous T-cell lymphoma treatment through multidisciplinary care, compartment-specific therapy selection, management of treatment-related complications like mogamalizumab-associated rash, and strategic use of combination therapies while addressing critical unmet needs including biomarker development and improved quality of life measures.

Vamsidhar Velcheti, MD, MBA, FASCO, FACP, FCCP; Jessica Donington, MD, MSCR; Jaspal Singh, MD; and Joshua Sabari, MD, discuss how optimizing early-stage non–small cell lung cancer (NSCLC) management through a multidisciplinary approach enhances treatment outcomes and improves patient care.

Andre Goy, MD; Jamie Koprivnikar, MD, and Harsh Parmar, MD, discuss how recent advancements in CAR T-cell therapies, bispecific antibodies, and targeted treatments are transforming the management of hematologic malignancies, with particular focus on real-world comparative analyses of different approaches in multiple myeloma, lymphoma, and leukemia.

Experts discuss the evolving treatment landscape in advanced renal cell carcinoma (RCC), focusing on optimal treatment selection and sequencing strategies, with insights from recent clinical trial updates presented at ASCO GU 2025 and their potential impact on clinical practice.

Shubham Pant, MD, MBBS; Haley Ellis, MD; Amit Mahipal, MD; and Darshil Shah, MD, MPH, examine the evolving landscape of biliary tract cancer management, covering critical aspects from initial prognosis communication through biomarker testing strategies, first-line immunotherapy combinations, and the emergence of HER2-targeted therapies, while highlighting recent clinical trial data and ongoing challenges in optimizing patient outcomes.

Neil M. Iyengar, MD; Sara A. Hurvitz, MD, FACP; Laura Huppert, MD; Anne P. O’Dea, MD; and Melinda L. Telli, MD, discuss how recent trials, particularly DESTINY-Breast04/06, TROPiCS-02, and TROPION-Breast01, have revolutionized the HER2-low/ultralow breast cancer treatment landscape, demonstrating efficacy of novel antibody-drug conjugates such as trastuzumab deruxtecan while emphasizing the importance of careful patient selection, standardized testing, and strategic sequencing of these emerging therapies.

Cesar Rodriguez, MD; Yvonne A. Efebera, MD; Natalia Neparidze, MD; and Omar Nadeem, MD, examine how treatment approaches for transplant-ineligible/deferred newly diagnosed multiple myeloma are evolving through clinical trials like CEPHEUS, IMROZ, and BENEFIT, which demonstrate improved outcomes with anti–CD38-based quadruplet regimens while considering factors such as MRD negativity, administration methods, and patient selection criteria for optimizing therapeutic strategies.

William J. Gradishar, MD, provides insights on the evolving treatment landscape of breast cancer management, highlighting updates to NCCN guidelines, the growing role of CDK4/6 inhibitors, and anticipated research findings at ASCO 2024.

Join leading global experts as they discuss the latest research and treatment advancements in CLL from the ASH 2024 Annual Meeting. Moderated by Dr. John Seymour, this peer exchange features in-depth insights from top clinicians across Europe.

Leading experts discuss the evolving treatment landscape in diffuse large B-cell lymphoma (DLBCL), focusing on front-line therapies, second-line immunotherapies, and strategies for managing relapsed/refractory cases."